XML 54 R77.htm IDEA: XBRL DOCUMENT v3.20.1
Collaborative and Other Relationships - Equity Method Investments (Details)
$ in Millions, ₩ in Billions
1 Months Ended 3 Months Ended
Nov. 30, 2018
USD ($)
Nov. 30, 2018
KRW (₩)
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Mar. 31, 2020
KRW (₩)
Jan. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2019
KRW (₩)
Nov. 07, 2018
USD ($)
Schedule of Equity Method Investments [Line Items]                    
Loss recorded on Samsung Bioepis joint venture     $ 0.0 $ 0.0            
Our share of Samsung Bioepis gains (losses)     14.8 28.7            
Collaboration profit (loss) sharing     71.8 58.1            
Total revenues     $ 3,534.3 $ 3,489.8            
Samsung Bioepis                    
Schedule of Equity Method Investments [Line Items]                    
Percentage of stake in entity       5.00%            
Percentage of stake in entity maximum     49.90%     49.90%        
Payments to acquire additional investment in equity method investment $ 676.6 ₩ 759.5     $ 676.6          
Amortization of basis differences                   $ 675.0
Loss recorded on Samsung Bioepis joint venture     $ 14.8              
Our share of Samsung Bioepis gains (losses)     (6.1)              
Amortization of basis differences     20.9              
Investment in Samsung Bioepis     $ 531.6     ₩ 651.1   $ 580.2 ₩ 670.8  
Biogen share of co-promotion profits or losses     50.00%              
Collaboration profit (loss) sharing     $ 71.8 $ 58.1            
Samsung Bioepis                    
Schedule of Equity Method Investments [Line Items]                    
Upfront and milestone payments made to collaborative partner     100.0              
Research and development expense     63.0              
Prepaid research and development expenses             $ 37.0      
Estimated additional payments upon achievement of development and commercial milestones     210.0              
Additional Milestone Payment             $ 15.0      
Contract Option Exercise Fee     60.0              
Due from Related Parties     3.8         85.0    
Due to Related Parties     19.8         $ 100.0    
Collaborative arrangement | Samsung Bioepis                    
Schedule of Equity Method Investments [Line Items]                    
Total revenues     $ 3.7 $ 24.8            
Inventory | Samsung Bioepis                    
Schedule of Equity Method Investments [Line Items]                    
Amortization of basis differences                   115.0
Equity method investment basis difference amortization period     1 year 6 months              
Developed technology | Samsung Bioepis                    
Schedule of Equity Method Investments [Line Items]                    
Amortization of basis differences                   615.0
Equity method investment basis difference amortization period     15 years              
In Process Research and Development | Samsung Bioepis                    
Schedule of Equity Method Investments [Line Items]                    
Amortization of basis differences                   170.0
Deferred tax liability | Samsung Bioepis                    
Schedule of Equity Method Investments [Line Items]                    
Amortization of basis differences                   $ 225.0